# Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

> **NCT00700713** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 181 (actual)

## Conditions studied

- Meningitis
- Meningococcemia

## Interventions

- **BIOLOGICAL:** Meningococcal polysaccharide diphtheria toxoid conjugate
- **BIOLOGICAL:** Meningococcal polysaccharide diphtheria toxoid conjugate
- **BIOLOGICAL:** Meningococcal polysaccharide diphtheria toxoid conjugate

## Key facts

- **NCT ID:** NCT00700713
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-02
- **Final completion:** 2009-03
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700713, "Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00700713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*